Stromal cells supporting cancer growth are emerging as importan targets for drugs and immunotherapies.

TK-002 is an innovative Cancer Vaccine vs a Stromal Antigen

  • Identified by our group as novel target for immunotherapy
  • Potential "Universal" Cancer Vaccine

Where we are:

  • Preclinical studies completed
  • Vectors (both Adeno and plasmid DNA) for human clinical use constructed
  • Biomarker assay under advanced development

Preferred Cancer Targets

  • Colon
  • Prostate
  • Stomach

Follow Us on Linkedin

Takis is a biotech dedicated to cancer research. Our primary objective is the development of innovative therapies based on the principle that our immune system can be “instructed” to recognize the tumor and reject it as a foreign entity.